Precede Biosciences
PrivateLast Round
Series B
Jan 12, 2026
Total Funding Raised
$140.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Precede Biosciences is a biotechnology company that offers a liquid biopsy platform for in-depth analysis of disease-related biology through a simple blood test.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Precede Biosciences Comparables
Compare Precede Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adela | 87% | |
| Aqtual | 85% | |
| Tagomics Ltd. | 82% |
Precede Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2026 | ||||
| Debt | Jan 12, 2026 | ||||
| Series A | Oct 5, 2023 |
Key People
Founding team and executive leadership
Precede Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Binney Street Capital | Seed, Series A, Series B |
| Osage University Partners | Series A, Series B |
| 5AM Ventures | Seed, Series B, Series A |
| Alexandria Venture Investments | Series B |
| Mirae Asset Capital Life Science | Series B |
| Mirae Asset Capital | Series B |
| Lilly Asia Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Launched Precede Bio Insight, an epigenomic liquid biopsy platform.
- Apr 17, 2026
Presented new data at the AACR 2026 Annual Meeting.
Precede Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Precede Biosciences's valuation, stock price, and market status.
Is Precede a public or private company?
Precede is a private company.
What is the current stock price of Precede?
Precede is a private company with no public stock price. No recent secondary market data is available.
How much is Precede worth (valuation)?
Valuation information for Precede is not publicly available.
Can I buy Precede stock?
Precede shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Precede's last funding round?
Precede's most recent funding round was Series A on October 5, 2023.
Who are the main investors in Precede?
Key investors in Precede include 5AM Ventures, Lilly Asia Ventures.
Will Precede IPO soon?
No public IPO plans have been announced for Precede.
How can I track Precede secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Precede's secondary market activity and sign up for updates.